Related Experiment Video

Updated: May 31, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Angiogenin as a molecular target for the treatment of prostate cancer

Shuping Li1, Soichiro Ibaragi, Guo-Fu Hu

  • 1Department of Pathology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.

Current Cancer Therapy Reviews
|July 12, 2011
PubMed

Insights

Angiogenin (ANG) is upregulated in prostate cancer, driving proliferation and angiogenesis. Blocking ANG shows promise for inhibiting cancer progression and developing new prostate cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Angiogenin (ANG), an angiogenic ribonuclease, is upregulated in human prostate cancers, particularly hormone-refractory diseases.
  • ANG is the most upregulated gene in Akt-driven prostate intraepithelial neoplasia (PIN) in mouse models.
  • ANG translocates to the nucleus, binding ribosomal DNA (rDNA) promoters to stimulate ribosomal RNA (rRNA) transcription.

Purpose of the Study:

  • To investigate the role of Angiogenin (ANG) in prostate cancer progression.
  • To evaluate ANG as a molecular target for prostate cancer therapy.

Main Methods:

  • The study examines ANG's function in prostate cancer cells and associated endothelial cells.
  • Various ANG antagonists were tested in animal models, including antisense oligonucleotides, siRNA, binding proteins, monoclonal antibodies, enzymatic inhibitors, and nuclear translocation blockers.

Main Results:

  • ANG promotes prostate cancer progression by stimulating cancer cell proliferation and tumor angiogenesis.
  • Multiple ANG antagonists demonstrated inhibition of prostate cancer in various animal models.

Conclusions:

  • Angiogenin (ANG) plays a critical role in prostate cancer development and progression.
  • ANG represents a promising molecular target for the development of novel prostate cancer therapeutics.

More Related Videos

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...